Health-related quality of life and disease symptoms in postmenopausal women with hr+, her2- advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy

Current Medical Research and Opinion

Volumn 29, Issue 11, 2013, Pages 1463-1473

  Campone, Mario ^a   Beck, J Thaddeus ^b   Gnant, Michael ^c   Neven, Patrick ^d   Pritchard, Kathleen I ^e   Bachelot, Thomas ^f   Provencher, Louise ^g   Rugo, Hope S ^h   Piccart, Martine ⁱ   Hortobagyi, Gabriel N ^j   Nunzi, Martina ^k   Heng, Daniel Y C ^l   Baselga, José ^m   Komorowski, Anna ⁿ   Noguchi, Shinzaburo ^o   Horiguchi, Jun ^p   Bennett, Lee ^q   Ziemiecki, Ryan ^q   Zhang, Jie ^r   Cahana, Ayelet ^r   Taran, Tetiana ^r   Sahmoud, Tarek ^r   Burris III, Howard A ^s   more..

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b Highlands Oncology Group   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e UNIVERSITY OF TORONTO   (Canada)

^f CENTRE LÉON BÉRARD   (France)

^g LAVAL UNIVERSITY   (Canada)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ JULES BORDET INSTITUTE   (Belgium)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^k Hospital of Terni   (Italy)

^l TOM BAKER CANCER CENTRE   (Canada)

^m MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁿ Hematology Oncology Associates of Rockland   (United States)

^o OSAKA UNIVERSITY   (Japan)

^p GUNMA UNIVERSITY HOSPITAL   (Japan)

^q RTI HEALTH SOLUTIONS   (United States)

^r NOVARTIS PHARMA AG   (Switzerland)

^s SARAH CANNON RESEARCH INSTITUTE   (United States)

more..

Author keywords

Advanced breast cancer; Everolimus; Exemestane; Health related quality of life; Hormone receptor positive

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; EXEMESTANE; HORMONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; POSTMENOPAUSE; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; QUESTIONNAIRE; SENSITIVITY ANALYSIS;

ADULT; AGED; ANDROSTADIENES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HEALTH STATUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; PLACEBOS; QUALITY OF LIFE; QUESTIONNAIRES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIROLIMUS; TREATMENT OUTCOME;

EID: 84885758013     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.836078     Document Type: Article

References (31)

1. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 2.2013. Fort Washington, PA: National Comprehensive Cancer Network. Available at: www.nccn.com [Last accessed 8 May 2013]
2. Cardoso F, Costa A, Norton L, et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012;21:242-52
3. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004;11:643-58 (Pubitemid 40065543)
4. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002;2:101-12 (Pubitemid 37328797)
5. Osborne CK, Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 2005;23:1616-22 (Pubitemid 46211414)
6. Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptorpositive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012;30:2718-24
7. Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009;27:2630-7
8. Boulay A, Rudloff J, Ye J, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005;11:5319-28 (Pubitemid 41003721)
9. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366:520-9
10. Afinitor (everolimus) tablets [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2012. Available at: http://www.accessdata. fda. gov/drugsatfda-docs/label/2012/022334s016lbl.pdf [Last accessed 8 May 2013]
11. Gotay CC, Lipscomb J, Snyder CF. Reflections on findings of the Cancer Outcomes Measurement Working Group: moving to the next phase. J Natl Cancer Inst 2005;97:1568-74 (Pubitemid 41662710)
12. Gerber B, Freund M, Reimer T. Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life. Dtsch Arztebl Int 2010;107:85-91
13. Montazeri A. Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res 2008;27:32
14. Hortobagyi GN, Piccart M, Rugo H, et al. Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 phase III trial. Cancer Res 2011;71(Suppl):105s-6s. Abstract S3-7
15. Burris 3rd HA, Lebrun F, Rugo HS, et al. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer 2013;119:1908-15
16. Piccart M, Noguchi S, Pritchard KI, et al. Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 phase III trial. J Clin Oncol 2012;30:21s. Abstract 559
17. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76 (Pubitemid 23073154)
18. Goodwin PJ, Black JT, Bordeleau LJ, et al. Health-related quality-of-life measurement in randomized clinical trials in breast cancer-taking stock. J Natl Cancer Inst 2003;95:263-81 (Pubitemid 36336477)
19. Sprangers MA, Groenvold M, Arraras JI, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 1996;14:2756-68 (Pubitemid 26329662)
20. Fayers PM, Aaronson NK, Bjordal K, et al. The EORTC QLQ-C30 Scoring Manual, 3rd edn. Brussels: European Organisation for Research and Treatment of Cancer, 2001
21. Rubin DB. Inference and missing data. Biometrika 1976;63:581-92
22. Michiels B, Molenberghs G, Bijnens L, et al. Selection models and patternmixture models to analyse longitudinal quality of life data subject to drop-out. Stat Med 2002;21:1023-41 (Pubitemid 34285489)
23. Little RJA. Pattern-mixture models for multivariate incomplete data. J Am Stat Assoc 1993;88:125-34
24. Hedeker D, Gibbons RD. Application of random-effects pattern-mixture models for missing data in longitudinal studies. Psychol Methods 1997;2:64-78 (Pubitemid 127453671)
25. Donaldson GW, Moinpour CM. Learning to live with missing quality-of-life data in advanced-stage disease trials. J Clin Oncol 2005;23:7380-4 (Pubitemid 46291794)
26. Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008;26:1664-70
27. Zhou X, Cella D, Cameron D, et al. Lapatinib plus capecitabine versus capecitabine alone for HER2\+ (ErbB2\+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res Treat 2009; 117:577-89
28. Yardley DA, Hortobagyi GN, Lebrun F, et al. Patient-reported physical, emotional, and social functioning in advanced breast cancer: insights from BOLERO-2. J Clin Oncol 2013;31:20s. Abstract 553
29. Hedeker D. An introduction to growth modeling. In: Kaplan D, ed. Quantitative Methodology for the Social Sciences. Thousand Oaks, CA: Sage Publications, 2004
30. Bottomley A, Biganzoli L, Cufer T, et al. Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study. J Clin Oncol 2004;22:2576-86 (Pubitemid 41103744)
31. Helgeson VS, Tomich PL. Surviving cancer: a comparison of 5-year diseasefree breast cancer survivors with healthy women. Psychooncology 2005;14:307-17 (Pubitemid 40533288)